Related Experiment Video
Updated: May 7, 2026
10:46
MRI and PET in Mouse Models of Myocardial Infarction
Published on: December 19, 2013
11.7K
Nanotechnology Innovations in Myocardial Infarction: Diagnosis, Treatment and the Way Forward
Wenhai Wang1, Dexin Xu2, Jian Ding3
1Department of Cardiology, Jilin Province FAW General Hospital, Changchun, 130000, China.
Journal of Cardiovascular Translational Research
|April 9, 2025
Summary
Nanotechnology offers advanced diagnostics and personalized treatments for myocardial infarction (MI). Innovations in nanoscale agents, imaging, and drug delivery promise improved patient outcomes and tissue repair, while ethical considerations are also discussed.
Area of Science:
- Biomedical Engineering
- Nanomedicine
- Cardiology
Background:
- Myocardial infarction (MI) presents a significant global health challenge, demanding continuous innovation in diagnosis and treatment.
- Current diagnostic and therapeutic strategies for MI require enhancement to improve patient outcomes.
- Nanotechnology presents promising avenues for revolutionizing MI management.
Purpose of the Study:
- To review innovative nanotechnology applications for early myocardial infarction diagnosis.
- To explore the role of nanoscale agents in cardiac biomarker identification.
- To examine advancements in nanotech-based therapeutics and regenerative medicine for MI.
Main Methods:
- Review of current literature on nanotechnology in cardiovascular disease.
- Analysis of nanoscale agents (nanoparticles, nanosensors) for biomarker detection.
- Evaluation of nanomedicine in imaging, drug delivery, and tissue regeneration.
Main Results:
- Nanoscale agents enable prompt and accurate identification of cardiac biomarkers for early MI diagnosis.
- Advancements in nanotech-enabled medical imaging improve therapeutic strategies and reduce cardiac injury.
- Nanoparticle-based drug delivery systems show potential for effective MI treatment with fewer side effects.
Conclusions:
- Nanotechnology significantly enhances early diagnosis and personalized treatment of myocardial infarction.
- Nanomaterials and nanodevices offer novel therapeutic strategies, including improved drug delivery and tissue regeneration.
- Addressing ethical and legal challenges is crucial for integrating nanotechnology into clinical practice for MI management.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...